Thermo Fisher Scientific Inc. $TMO Shares Purchased by Wilson Asset Management International PTY Ltd.

Wilson Asset Management International PTY Ltd. boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 33,270 shares of the medical research company’s stock after purchasing an additional 1,625 shares during the quarter. Thermo Fisher Scientific comprises 4.9% of Wilson Asset Management International PTY Ltd.’s holdings, making the stock its 8th largest position. Wilson Asset Management International PTY Ltd.’s holdings in Thermo Fisher Scientific were worth $19,278,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of TMO. Beacon Financial Strategies CORP acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Olistico Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth approximately $28,000. Cloud Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at $31,000. Finally, Thurston Springer Miller Herd & Titak Inc. increased its stake in shares of Thermo Fisher Scientific by 195.7% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 68 shares of the medical research company’s stock valued at $39,000 after buying an additional 45 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. TD Cowen lowered their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Barclays lowered their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. UBS Group reissued a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. DZ Bank started coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 price target for the company. Finally, Wells Fargo & Company set a $683.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $623.05.

Insiders Place Their Bets

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 5,800 shares of company stock valued at $2,963,544 in the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $466.74 on Wednesday. The stock has a 50-day moving average price of $495.23 and a 200 day moving average price of $547.61. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The firm has a market cap of $173.45 billion, a price-to-earnings ratio of 25.66, a PEG ratio of 2.05 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period last year, the company earned $5.15 earnings per share. The company’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were issued a dividend of $0.47 per share. The ex-dividend date of this dividend was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.